PEA (Palmitoylethanolamide)

Palmitoylethanolamide is an endogenous fatty acid amide, produced by the body on demand in response to cellular stress. It belongs to a family of compounds related to the endocannabinoid system, though it does not bind cannabinoid receptors directly.

It is also present in small amounts in foods including egg yolk, soy lecithin and peanuts. It was first identified in the 1950s during research into anti-inflammatory factors in food, so despite feeling like a new arrival it has a long research history, largely European.

PEA is poorly water soluble, and particle size materially affects absorption. Micronised and ultra-micronised preparations were developed to address this, and most of the clinical research uses them. A non-micronised product is not equivalent, and this is one of the clearer cases where a formulation claim is genuinely substantiated.

The primary mechanism involves activation of PPAR-alpha, a nuclear receptor that regulates transcription of genes involved in inflammatory signalling and lipid metabolism. This is a genomic effect, which helps explain why benefits accrue over weeks rather than acutely.

PEA also calms the immune cells that sit in tissue and release inflammatory mediators. Those mediators sensitise nearby nerve endings, and dampening that process is proposed as central to its effects on persistent discomfort.

An indirect entourage effect has also been described, whereby PEA increases the activity of the body's own cannabinoid-like signalling molecules by competing for the enzymes that degrade them. This produces related effects without PEA itself binding those receptors.

The human literature is larger than most people expect, with a considerable number of trials conducted principally in Italy and elsewhere in Europe over several decades. Meta-analyses of trials in various persistent discomfort conditions have generally reported meaningful reductions compared with control.

Trials have covered nerve-related discomfort, low back complaints, joint conditions and pelvic conditions, with reasonably consistent direction of effect. Tolerability across this literature is notably good.

The caveats are geographic concentration of the research, variable trial quality, and industry involvement in a share of it. Independent replication outside Europe remains limited. Even so, this is a better-evidenced ingredient than its low profile in the UK market suggests.

PEA has an unusually clean tolerability profile across the trial literature. Adverse effects reported are few and generally comparable to placebo, most commonly mild digestive discomfort.

Being a compound the body produces itself, and one present in common foods, contributes to that profile. No dependence, tolerance or withdrawal has been described, and no significant drug interactions have been established.

Long-term data beyond the durations used in trials is limited, and safety in pregnancy has not been established. Anyone using it for persistent discomfort should be doing so alongside proper medical assessment rather than instead of it.